- Home
- HSII vs ANNX Comparison
HSII vs ANNX Comparison
Compare HSII & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- ANNX
- Stock Information
- Founded
- HSII 1953
- ANNX 2011
- Country
- HSII United States
- ANNX United States
- Employees
- HSII N/A
- ANNX N/A
- Industry
- HSII Diversified Commercial Services
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- ANNX Health Care
- Exchange
- HSII Nasdaq
- ANNX Nasdaq
- Market Cap
- HSII 753.6M
- ANNX 668.8M
- IPO Year
- HSII 1999
- ANNX 2020
- Fundamental
- Price
- HSII $44.78
- ANNX $6.12
- Analyst Decision
- HSII Buy
- ANNX Strong Buy
- Analyst Count
- HSII 2
- ANNX 7
- Target Price
- HSII $42.00
- ANNX $15.80
- AVG Volume (30 Days)
- HSII 146.4K
- ANNX 1.2M
- Earning Date
- HSII 11-04-2024
- ANNX 11-14-2024
- Dividend Yield
- HSII 1.34%
- ANNX N/A
- EPS Growth
- HSII N/A
- ANNX N/A
- EPS
- HSII 1.83
- ANNX N/A
- Revenue
- HSII $1,075,544,000.00
- ANNX N/A
- Revenue This Year
- HSII $7.32
- ANNX N/A
- Revenue Next Year
- HSII $3.09
- ANNX N/A
- P/E Ratio
- HSII $24.51
- ANNX N/A
- Revenue Growth
- HSII 6.55
- ANNX N/A
- 52 Week Low
- HSII $26.52
- ANNX $2.27
- 52 Week High
- HSII $49.02
- ANNX $8.40
- Technical
- Relative Strength Index (RSI)
- HSII 60.22
- ANNX 30.04
- Support Level
- HSII $46.36
- ANNX $6.85
- Resistance Level
- HSII $49.02
- ANNX $7.63
- Average True Range (ATR)
- HSII 1.51
- ANNX 0.32
- MACD
- HSII 0.33
- ANNX -0.17
- Stochastic Oscillator
- HSII 59.58
- ANNX 6.22
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.